# Type 2 Diabetes Remission via Weight Loss: What DiRECT, DIADEM-I, and STAMPEDE Actually Show About the 15 kg Threshold > **Summary:** DiRECT put 46% of participants into remission at 1 year and 36% at 2 years with primary-care VLCD. Here's the ADA/EASD definition, the ~15 kg threshold, and how DIADEM-I and STAMPEDE fit. > **Publisher:** WeightFAQ > **Author:** WeightFAQ Staff > **Published:** 2026-07-08 > **Updated:** 2026-07-08 > **Canonical URL:** https://weightfaq.com/weight-loss/type-2-diabetes-remission-weight-loss/ > **Content type:** Evergreen guide > **Tags:** type 2 diabetes, remission, DiRECT, DIADEM-I, STAMPEDE, clinical trials, weight loss > **Image:** https://weightfaq.com/_astro/type-2-diabetes-remission-weight-loss-hero.ChcE7Rom.webp — Adult patient in a bright primary-care clinic reviewing a printed A1c trend chart with a physician holding a printed 12-week food-reintroduction plan, a glucometer, stethoscope, and cloth measuring tape on the desk. **Type 2 diabetes remission** — an HbA1c below 6.5% sustained off all glucose-lowering medication — is real, replicated, and, in early disease, reachable with a defined amount of weight loss. The clearest signal comes from the **DiRECT trial** (**Lean 2018, *Lancet***), a UK primary-care randomized study in which **46% of the very-low-calorie diet (VLCD) arm reached remission at 1 year** versus 4% of the control arm. At two years, 36% were still in remission (**Lean 2019, *Lancet Diabetes and Endocrinology***); at five years, about 11% overall — but 64% of those who kept off at least 10 kg (**Lean 2024, *Lancet Diabetes and Endocrinology***). **DIADEM-I** (**Taheri 2020, *Lancet Diabetes and Endocrinology***) replicated the finding in a MENA population with 61% remission at 1 year in early diabetes. The mechanism is Roy Taylor's **twin-cycle hypothesis**: ectopic fat in the liver and pancreas drives hepatic insulin resistance and beta-cell de-differentiation, and weight loss below an individual's **personal fat threshold** clears it (**Taylor 2018, *Cell Metabolism***). This guide covers the ADA/EASD 2021 remission definition, the four-driver mechanism, what DiRECT, DIADEM-I, Look AHEAD, and STAMPEDE actually show, a five-step DiRECT-style protocol, and how lifestyle, bariatric surgery, and GLP-1 medications compare on 1- and 5-year remission rates. ## Who this is for — and who it is not for This guide is for adults with **type 2 diabetes** — especially within about six years of diagnosis and not yet insulin-dependent — who want to understand whether **remission** is realistically achievable through weight loss, and what the evidence-based protocol looks like. It is **not** for: - **Type 1 diabetes** — an autoimmune loss of beta-cell mass; the twin-cycle mechanism does not apply. See our [type 1 diabetes and weight loss](https://weightfaq.com/weight-loss/type-1-diabetes-and-weight-loss/) guide. - **Monogenic (MODY) diabetes** — remission genetics are different; specialist input is required. - **Long-standing insulin-requiring type 2 diabetes with markedly reduced beta-cell reserve** — remission is much less likely, and deprescribing is higher risk. HbA1c reduction and cardiovascular protection remain worthwhile targets — see [cardiovascular disease and weight loss](https://weightfaq.com/weight-loss/cardiovascular-disease-and-weight-loss/) for the SELECT-era MACE evidence that applies here — but the DiRECT model was not designed for this group. - **Type 2 diabetes with active DKA, hyperosmolar hyperglycemic state, or a recent cardiovascular event** — stabilize first, then discuss weight-loss protocols with the treating clinician. If you have **prediabetes** rather than diabetes, the intervention conversation is prevention rather than remission — see our [prediabetes and weight loss](https://weightfaq.com/weight-loss/prediabetes-and-weight-loss/) and [diabetes prevention program](https://weightfaq.com/weight-loss/diabetes-prevention-program/) guides. If your broader picture is central adiposity plus insulin resistance without an A1c in the diabetic range, see [metabolic syndrome and weight loss](https://weightfaq.com/weight-loss/metabolic-syndrome-and-weight-loss/). ## The remission definition — 5-row primer The 2021 ADA/EASD consensus (**Riddle 2021**) supersedes the older 2009 Buse definition and is the framework every current trial and guideline uses. | Term | Threshold | Duration | Medication status | Notes | | --- | --- | --- | --- | --- | | **Remission (2021 ADA/EASD)** | HbA1c < 6.5% (48 mmol/mol) | ≥ 3 months | Off all glucose-lowering medication, including GLP-1 receptor agonists and SGLT2 inhibitors | Current standard; the definition used by DiRECT 2 y and 5 y and by remission registries | | **Partial remission (2009, older)** | HbA1c 5.7–6.4% | ≥ 1 year | Off medication | Superseded — still appears in older papers | | **Complete / prolonged remission (2009, older)** | HbA1c < 5.7% | ≥ 5 years | Off medication | Rare in real-world data; mostly a research concept | | **Confounders that can invalidate an A1c** | — | — | — | SGLT2 washout, GLP-1 washout, honeymoon phase after diagnosis, hemoglobinopathy, iron-deficiency anemia, recent transfusion — an HbA1c under these conditions may not reflect true glycemic status | | **What remission is NOT** | — | — | — | Cure; permanent; guaranteed to hold if weight is regained; a signal that microvascular surveillance can stop | ## The four-driver mechanism — Taylor's twin cycle Roy Taylor's **twin-cycle hypothesis** (**Taylor 2018, *Cell Metabolism***) explains why type 2 diabetes is mechanically reversible in many people and why weight loss below an individual threshold — not below a population BMI — is the trigger. **Driver 1 — hepatic fat and fasting hyperglycemia.** Excess energy intake drives triglyceride storage in the liver. A fatty liver becomes insulin-resistant and over-produces glucose overnight, elevating fasting glucose. The pancreas compensates by secreting more insulin, encouraging more fat storage — the cycle self-reinforces. **Driver 2 — pancreatic fat and beta-cell de-differentiation.** Fat eventually accumulates inside the pancreas, and lipotoxicity drives beta cells to dedifferentiate — losing insulin-secretory identity rather than dying outright (**Steven 2016**). Post-meal glucose rises, and the clinical diagnosis emerges. **Driver 3 — weight loss depletes ectopic fat in a predictable order.** In the Counterbalance study (**Taylor 2013, *Diabetologia***), an 8-week 600–800 kcal/day VLCD cleared liver fat within days (fasting glucose normalized in a week) and pancreatic fat over about 8 weeks (beta-cell function partially recovered). Weight loss below the personal fat threshold is what allows this depletion. **Driver 4 — the personal fat threshold (Taylor 2015, 2020).** Each person has an individual capacity for ectopic fat storage before the twin cycle activates — and this capacity is **not tightly linked to BMI**. South Asian and East Asian populations often cross the threshold at a BMI of 25 or lower, which is why DIADEM-I found high remission rates in adults who by Western BMI cutoffs would not appear obese. Remission occurs when you cross **below your own** threshold, not below any universal weight. For related mechanisms of hepatic fat and metabolic dysfunction, see our [insulin resistance and weight loss](https://weightfaq.com/weight-loss/insulin-resistance-weight-loss/) and [resmetirom (Rezdiffra) for MASH](https://weightfaq.com/weight-loss/resmetirom-rezdiffra-for-mash/) guides — DiRECT-style loss reverses steatohepatitis on the same weight trajectory that reverses diabetes. ## What the evidence actually shows **DiRECT (Lean 2018, 2019, 2024).** In a UK primary-care randomized trial of 306 adults with type 2 diabetes of less than six years' duration and BMI 27–45, an intensive lifestyle arm (12–20 weeks of total diet replacement at ~825 kcal/day, stepped food reintroduction, and long-term weight-loss maintenance support) produced **46% remission at 1 year vs 4% in the control arm** (**Lean 2018, *Lancet***). At 2 years, remission was **36% vs 3%** (**Lean 2019, *Lancet Diab Endo***). Remission was tightly linked to sustained weight loss: **86% of those who kept off ≥ 15 kg** were in remission at 2 years. At 5-year follow-up, overall remission had fallen to about 11%, but participants who kept off at least 10 kg had remission of roughly 64% (**Lean 2024, *Lancet Diab Endo***). The takeaway is durable at the group level and clear at the individual level: hold the weight, hold the remission. **DIADEM-I (Taheri 2020, *Lancet Diab Endo*).** A primary-care VLCD trial in Qatar, Kuwait, and the UAE recruited 158 adults with type 2 diabetes diagnosed within the previous three years. **61% of the intensive arm were in remission at 1 year vs 12% of usual-care controls.** DIADEM-I was decisive on two points: DiRECT-style remission generalizes outside a Northern European population, and duration of diabetes at enrollment matters — earlier is better. **Look AHEAD (Gregg 2012, *JAMA*).** In the multi-center Look AHEAD lifestyle-intervention trial for established type 2 diabetes, an intensive lifestyle intervention reduced weight by ~8.6% at 1 year and produced **partial remission in 11.5% of participants at year 1** vs 2% in usual care. Look AHEAD ran a less aggressive protocol than DiRECT (moderate calorie deficit, portion-controlled meal plan) and enrolled adults with longer-duration diabetes — both features predict lower remission rates. The signal was real but weaker. **STAMPEDE (Schauer 2017, *N Engl J Med*).** The Cleveland Clinic STAMPEDE trial randomized 150 adults with type 2 diabetes and BMI 27–43 to intensive medical therapy alone, medical therapy plus **Roux-en-Y gastric bypass**, or medical therapy plus **sleeve gastrectomy**. At 5 years, remission (HbA1c ≤ 6.0% off medication) reached **29% with bypass, 23% with sleeve, and 5% with medical therapy alone**. STAMPEDE anchors the bariatric benchmark and shows the surgical remission signal is durable. **SURMOUNT-2 and SURPASS (Jastreboff 2023; Frías 2021; Rosenstock 2021).** The tirzepatide and semaglutide trial programs in type 2 diabetes produce weight loss in DiRECT territory (12–22%) and HbA1c reductions of 2.0–2.5 points from baseline. But these results include the direct drug effect on insulin secretion and gastric emptying — they do not meet the ADA/EASD remission definition, which requires 3 months off the medication. ## Time course — what happens over hours, weeks, and years The DiRECT and Counterbalance timelines show a striking pattern: **liver fat clears in days, pancreas fat clears in weeks, and the remission-durability curve is set in years**. | Timepoint | What is happening | Source | | --- | --- | --- | | **Day 1 of VLCD** | Glycogen and water losses account for the first 1–3 kg; insulin levels drop | Lim 2011 | | **Day 7** | Fasting glucose approaches normal as intrahepatic triglyceride depletes | Lim 2011; Taylor 2013 | | **Week 8** | Pancreatic fat approaches non-diabetic levels; first-phase insulin response begins to recover | Taylor 2013 (Counterbalance) | | **Month 6** | Peak weight loss on the DiRECT protocol; the majority of remission events are captured by this point | Lean 2018 | | **Year 2** | Remission durability begins to correlate strongly with maintained weight loss | Lean 2019 | | **Year 5** | Overall remission ~11%; ~64% among those who maintained ≥ 10 kg off | Lean 2024 | ## Five-step "how to actually attempt remission" protocol This is **not medical advice** — it is a description of the DiRECT protocol so that readers know what a physician-supervised remission attempt looks like. **Step 1 — Screen for candidacy.** Diabetes duration under about six years, BMI ≥ 27, not on insulin, no active DKA history, no severe cardiovascular disease within the last six months, and a treating clinician willing to co-manage medication withdrawal. **Step 2 — Coordinate medication withdrawal.** With a physician, withdraw **insulin and sulfonylureas first** (before beginning the VLCD, to avoid hypoglycemia). SGLT2 inhibitors are usually paused with attention to euglycemic DKA risk. GLP-1 receptor agonists are typically discontinued as weight loss reduces the need. **Metformin is usually last** — it is the safest, and by the point it comes off, HbA1c has been non-diabetic for weeks. **Step 3 — Total diet replacement at ~825 kcal/day for 12 weeks.** In DiRECT this used a formulaic meal-replacement (**Optifast** or similar) providing complete micronutrients. VLCDs at this intensity are for medical use and require monitoring for hypoglycemia, orthostatic symptoms, gout flares, and gallstone risk — the full clinical protocol, medication triggers, and phase-by-phase monitoring are in our [very-low-calorie diets](https://weightfaq.com/weight-loss/very-low-calorie-diets/) guide. **Step 4 — Structured food reintroduction over 4–8 weeks.** Guided by a dietitian, gradually re-introduce whole foods while tracking weight, fasting glucose, and appetite. This step is often where adherence starts to slip; structured coaching contact matters. **Step 5 — Long-term weight-loss maintenance protocol.** The single biggest failure point in DiRECT was regain during years 2–5 — see [weight-loss maintenance](https://weightfaq.com/weight-loss/weight-loss-maintenance/) for the evidence-based approach (weekly weigh-ins, high protein, resistance training, cognitive-behavioral relapse-prevention). Remission durability is essentially weight-maintenance durability. ## Treatment comparison — 1-year and 5-year remission rates | Option | Typical weight loss | 1-year remission | 5-year remission | Trial anchor | | --- | --- | --- | --- | --- | | **DiRECT intensive VLCD lifestyle** | ~13 kg at 12 mo; ~9 kg at 24 mo | ~46% | ~11% overall (64% if ≥10 kg kept off) | Lean 2018 / 2019 / 2024 | | **Look AHEAD moderate lifestyle** | ~8.6% at 12 mo | ~11.5% partial remission | Not designed to sustain remission | Gregg 2012 | | **Bariatric surgery (RYGB / sleeve)** | 25–30% of body weight | ~40–60% | ~23–29% | Schauer 2017 (STAMPEDE) | | **GLP-1 / GIP-GLP-1 (semaglutide, tirzepatide)** | 12–22% at 12–18 mo | HbA1c normalization common but does not meet ADA/EASD remission (on-drug) | Not established off-drug | Jastreboff 2023; Frías 2021 | | **Metformin alone** | ~2 kg | Not designed to induce remission | ~0% | ADA 2024 Standards of Care | | **Dietary weight-neutral A1c-lowering (e.g. Mediterranean without deficit)** | Minimal | Rare | Not established | PREDIMED-Plus is the closest analog | The comparison chart in [bariatric surgery vs GLP-1 medications](https://weightfaq.com/weight-loss/bariatric-surgery-vs-glp-1-medications/) covers the surgical-vs-pharmacologic decision in more detail; the same trade-offs shape a lifestyle-vs-surgery remission choice. ## Special situations ### Newly diagnosed vs long-standing diabetes DiRECT restricted enrollment to under six years since diagnosis, and even within that window shorter duration predicted higher remission. DIADEM-I limited to under three years. Beyond about ten years, beta-cell reserve is usually depleted enough that full remission is uncommon, though HbA1c improvement and medication reduction remain worthwhile targets. ### Insulin-dependent type 2 diabetes Remission is technically possible but the medication-withdrawal side of the protocol is materially higher-risk. Insulin dosing typically has to drop dramatically within the first days of a VLCD; without careful monitoring, hypoglycemia risk is high. This is a specialty-endocrinology protocol, not a primary-care one. ### Chronic kidney disease (CKD) SGLT2 inhibitors and GLP-1 receptor agonists have independent kidney and cardiovascular benefits that a remission protocol removes. In CKD stages 3–5, coordinate with nephrology before withdrawing either class — see our [chronic kidney disease and weight loss](https://weightfaq.com/weight-loss/chronic-kidney-disease-and-weight-loss/) guide. VLCDs in CKD require specialist monitoring. ### MASH / fatty liver disease DiRECT-style loss reverses steatosis and often reverses steatohepatitis on the same weight-loss timeline that reverses diabetes. See [resmetirom (Rezdiffra) for MASH](https://weightfaq.com/weight-loss/resmetirom-rezdiffra-for-mash/). ### Ozempic-face and rapid loss Rapid weight loss of 15–25% often produces cosmetic changes covered in [Ozempic face and weight loss](https://weightfaq.com/weight-loss/ozempic-face-and-weight-loss/); a DiRECT-style VLCD produces the same effect on a shorter timeline. ### Post-bariatric conversion Some adults enter remission after bariatric surgery, regain weight, and lose remission; the surgical-to-medical-therapy conversion pathway is covered in [bariatric surgery vs GLP-1 medications](https://weightfaq.com/weight-loss/bariatric-surgery-vs-glp-1-medications/). ### South Asian and East Asian populations Personal fat thresholds tend to be lower — an adult with a BMI of 25 may already have crossed threshold. DIADEM-I is the strongest evidence for effective remission at lower BMIs, and international guidelines now recommend earlier screening and lower BMI thresholds for these populations. ### Older adults In adults over 70, deprescribing risk (hypoglycemia, falls, sarcopenia) usually dominates. Full remission is less commonly the primary goal — HbA1c targets are individualized and moderate loss with medication simplification often provides most of the benefit. See our [weight loss for older adults](https://weightfaq.com/weight-loss/weight-loss-for-older-adults/) guide. For the glycemic-control-exercise add-on specifically, [tai chi for weight loss](https://weightfaq.com/weight-loss/tai-chi-for-weight-loss/) is one of the best-supported low-impact modalities in the T2D and prediabetes literature — Zhao 2020 (*Complement Ther Med*) meta of 14 RCTs pooled a ~0.5–1.0 kg/m² BMI reduction and ~0.3–0.5% HbA1c reduction over 12 weeks at 3 sessions per week, and the fall-prevention bonus (47.5% risk reduction per Wolf 1996) directly protects the deprescribing window. ## Six myths and red flags — what to correct - **"Type 2 diabetes is always progressive and never reversible."** DiRECT, DIADEM-I, and STAMPEDE all show it is often reversible in early disease. It is not always reversible — beta-cell reserve matters — but the "always progressive" framing is out of date. - **"You need bariatric surgery to reverse type 2 diabetes."** DiRECT achieved 46% remission at 1 year in primary care with no surgery. Bariatric surgery does outperform lifestyle at 5 years, but it is not required for remission. - **"Any weight loss will produce remission."** The signal clusters around **~15 kg** or roughly 15% of body weight for most adults. A 3–5% loss lowers HbA1c meaningfully but rarely produces remission. - **"Remission means cure — you can stop worrying about diabetes forever."** Remission is not cure. Beta-cell function and metabolic vulnerability remain. Continue microvascular surveillance and monitor HbA1c on the same schedule. - **"Keto is the only diet that reverses diabetes."** DiRECT used a formula VLCD, not keto. Mediterranean, low-carb, and total-diet-replacement patterns can all produce the needed weight loss; the active ingredient is the sustained energy deficit and the ectopic-fat depletion it drives. - **"Metformin prevents remission."** Metformin is compatible with remission attempts and is usually the last drug withdrawn. It does not block the twin-cycle-reversing effect of weight loss. **Emergency lines:** call **911** for suspected DKA (fruity breath, deep rapid breathing, vomiting, confusion) or HHS during any low-calorie protocol, and call your clinician for a **fasting glucose below 70 mg/dL** while off medication. Call or text **988** for behavior-change or eating-disorder crisis. ## Bottom line Type 2 diabetes remission is real, replicated across DiRECT, DIADEM-I, Look AHEAD, and the bariatric literature, and defined precisely enough (**HbA1c < 6.5% off all glucose-lowering medication for ≥ 3 months**, ADA/EASD 2021) that clinicians and patients can hold themselves to the same standard as the trials. The evidence-based path is **early diagnosis, ~15 kg sustained weight loss, physician-supervised medication withdrawal, and structured long-term maintenance**. Remission is not cure — durability tracks weight-maintenance durability — but for adults within about six years of diagnosis, the DiRECT protocol offers a genuine, well-replicated chance at putting the disease behind them.

Sources